Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Pharmaceuticals

    Pharmaceuticals - Page 55

    Bayer, plaintiffs to postpone more glyphosate lawsuits for settlement talks

    Bayer, plaintiffs to postpone more glyphosate lawsuits for settlement talks

    Medical Dialogues Bureau9 Dec 2019 9:00 AM IST
    Bayer acquired the weed killer brands last year as part of a $63 billion takeover of Monsanto, has ruled out pulling the products from the U.S....
    Govt action against BioMed contaminated polio vaccine supply; Minister informs RS

    Govt action against BioMed contaminated polio vaccine supply; Minister informs RS

    Farhat Nasim8 Dec 2019 11:30 AM IST
    New Delhi: The Minister in the Ministry of Health and Family Welfare, Ashwini Kumar Choubey recently informed the Parliament about the action taken by...
    Dabur eyes to acquire firms, expand in rural India with Rs 3500 crore war chest: Report

    Dabur eyes to acquire firms, expand in rural India with Rs 3500 crore war chest: Report

    Farhat Nasim8 Dec 2019 9:45 AM IST
    “We have a ready war chest available to acquire companies,” Malhotra said, adding that Dabur has reserves of up to 35 billion rupees ($490 million)....
    Generic versions of Novartis blockbuster MS drug Gilenya gets USFDA green flag

    Generic versions of Novartis blockbuster MS drug Gilenya gets USFDA green flag

    Medical Dialogues Bureau8 Dec 2019 9:38 AM IST
    The approval allows HEC Pharm Co Ltd, Biocon Ltd and Sun Pharmaceutical Industries Ltd to produce Gilenya for the treatment of relapsing forms of MS...
    AstraZeneca-Merck cancer drug Lynparza wins approval in China

    AstraZeneca-Merck cancer drug Lynparza wins approval in China

    Medical Dialogues Bureau8 Dec 2019 9:20 AM IST
    Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, AstraZeneca and Merck...
    GSK seeks USFDA approval for investigational HIV treatment Fostemsavir

    GSK seeks USFDA approval for investigational HIV treatment Fostemsavir

    Medical Dialogues Bureau8 Dec 2019 9:15 AM IST
    GSK Plc's Fostemsavir is being developed for use in combination with other antiretroviral agents in adults who have been previously taken treatments...
    Enzyvant regenerative therapy for rare immune disorder rejected by USFDA over manufacturing concerns

    Enzyvant regenerative therapy for rare immune disorder rejected by USFDA over manufacturing concerns

    Medical Dialogues Bureau8 Dec 2019 9:02 AM IST
    Enzyvant was hoping to win its first approval for the therapy, RVT-802, aimed at treating congenital athymia, a disorder affecting babies born without...
    UCB psoriasis drug Bimekizumab beats AbbVie blockbuster Humira in late-stage trial

    UCB psoriasis drug Bimekizumab beats AbbVie blockbuster Humira in late-stage trial

    Medical Dialogues Bureau8 Dec 2019 8:59 AM IST
    UCB's drug, Bimekizumab, also met the main goal of clearing or almost clearing the skin of plaques or rashes in a late-stage study, as assessed by an...
    Dr Reddys launches generic version of Hemabate injection indicated for abortion in US

    Dr Reddys launches generic version of Hemabate injection indicated for abortion in US

    Medical Dialogues Bureau7 Dec 2019 12:46 PM IST
    Carboprost Tromethamine injection for aborting a pregnancy is a generic version of Pfizer's Hemabate injection in the strength of 250 mcg/mL, Dr...
    Take action against chemists selling prescription drugs OTC sans authorization: HC directs Govt

    Take action against chemists selling prescription drugs OTC sans authorization: HC directs Govt

    Medical Dialogues Bureau7 Dec 2019 10:07 AM IST
    The petition had alleged that chemists dealing in the retail sale of medicines are selling antibiotics and medicines mentioned in Schedule H and H1 of...
    Diabetes drug Metformin under USFDA lens for presence of cancer-causing impurities

    Diabetes drug Metformin under USFDA lens for presence of cancer-causing impurities

    Medical Dialogues Bureau7 Dec 2019 9:35 AM IST
    Metformin is a first-line medication for the treatment of type 2 diabetes. It helps control high blood sugar and is marketed under a number of brand...
    Eli Lilly new cancer research unit Loxo Oncology to be run by Loxo executives

    Eli Lilly new cancer research unit Loxo Oncology to be run by Loxo executives

    Medical Dialogues Bureau7 Dec 2019 9:15 AM IST
    The new unit, to be called Loxo Oncology at Lilly, will include experimental cancer drugs from both Eli Lilly's and Loxo's developmental pipelines.New...
    PrevNext

    Popular Stories

    BA/BE study applications have to be processed in 15 days: CDSCO

    BA/BE study applications have to be processed in 15 days: CDSCO

    Religare Enterprises to divest stake in arm to Kedaara for Rs 200 crore

    Religare Enterprises to divest stake in arm to Kedaara for Rs 200 crore

    What Makes Group Medical Insurance Cheaper than Individual Insurance

    What Makes Group Medical Insurance Cheaper than Individual Insurance

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    Coronavirus: CDSCO issues guidelines to be followed while visiting CDSCO office.

    Coronavirus: CDSCO issues guidelines to be followed while visiting CDSCO office.

    Embracing the Vegetarian Lifestyle: 5 Habits You Need to Have Right Away

    Embracing the Vegetarian Lifestyle: 5 Habits You Need to Have Right Away

    OncoStem Diagnostics named

    OncoStem Diagnostics named 'Best Innovation- Cancer Risk Assessment' by NASSCOM Life sciences and...

    Protect Your Loved Ones with a Term Plan that’s Smart

    Protect Your Loved Ones with a Term Plan that’s Smart

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok